|
Real-time Estimate
Cboe BZX
20:25:11 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 7.120 USD | -0.14% |
|
+9.06% | +126.11% |
| 10-25 | Agenus Inc. Reports Early Phase 2 Results From dMMR Colon Cancer Cohort Of NEOASIS Study | CI |
| 10-08 | Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination | MT |
Company Valuation: Agenus Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 827 | 731.5 | 315.8 | 64.28 | 106.8 | 321 | - | - |
| Change | - | -11.54% | -56.83% | -79.65% | 66.13% | 200.6% | - | - |
| Enterprise Value (EV) | 827 | 731.5 | 315.8 | 64.28 | 106.8 | 321 | 321 | 321 |
| Change | - | -11.54% | -56.83% | -79.65% | 66.13% | 200.6% | 0% | 0% |
| P/E | -29.3x | -3.08x | -1.2x | -0.26x | - | 28.9x | -15.1x | -15.3x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0.1x | 0x | - | - | 0x | 8.69x |
| Capitalization / Revenue | 2.8x | 7.46x | 2.02x | 0.62x | 0.94x | 2.56x | 2.77x | 2.49x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.56x | 2.77x | 2.49x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | 6.06x | 12.2x | -84.5x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -6.41x | -14.4x | -6.72x |
| FCF Yield | -2.86% | -31.2% | -74.1% | -247% | -72.3% | -15.6% | -6.95% | -14.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.2 | -15.6 | -13.8 | -10.59 | - | 0.2467 | -0.4733 | -0.465 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 295.7 | 98.02 | 156.3 | 103.5 | 114.2 | 125.2 | 116 | 129.1 |
| EBITDA | - | -154.1 | - | - | - | - | - | - |
| EBIT 1 | 25.75 | -179.4 | -159.5 | -124.4 | -20.17 | 53 | 26.4 | -3.8 |
| Net income 1 | -24.14 | -230.7 | -257.4 | -232.3 | -0.101 | 39.4 | -28.55 | -53.55 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 64.400 | 48.000 | 16.558 | 2.740 | 3.140 | 7.130 | 7.130 | 7.130 |
| Nbr of stocks (in thousands) | 12,842 | 15,241 | 19,075 | 23,459 | 34,008 | 45,020 | - | - |
| Announcement Date | 01/03/22 | 14/03/23 | 14/03/24 | 11/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 28.91x | - | - | - | 321M | |
| 16.92x | 6.39x | 12.26x | 1.77% | 64.14B | |
| 30.57x | 8.11x | 26.59x | 0.05% | 55.53B | |
| 36.68x | 6.52x | 19.45x | 0.88% | 53.03B | |
| 35.39x | 3.41x | 14.74x | -.--% | 45.99B | |
| 49.25x | 5.68x | 31.09x | -.--% | 42.45B | |
| -19.59x | 189.6x | -20.86x | -.--% | 40.45B | |
| 31.7x | 8.06x | 20.96x | 0.41% | 32.25B | |
| 47.12x | 8.37x | 28.08x | -.--% | 34.47B | |
| 27.96x | 5.9x | 15.29x | -.--% | 24.23B | |
| Average | 28.49x | 26.89x | 16.40x | 0.34% | 39.29B | |
| Weighted average by Cap. | 27.97x | 25.38x | 16.46x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AGEN Stock
- Valuation Agenus Inc.
Select your edition
All financial news and data tailored to specific country editions
